linjc16/ctgov huggingface dataset:
Abnormal Placenta Plant Disease Early Diagnosis and Individualized Treatment Research

Study Overview
=================
Brief Summary
-----------------
As the two-child policy implementation, caesarean women's clinical pregnancy is a huge problem again, Especially the placenta planting abnormal disease is a serious threat to the maternal health and life. Through this research, the investigators can obtain relevant epidemiological data and provide objective data for the department of public health policy; Predicting an placenta abnormal planting early diagnosis model was constructed, it will fill the blank in this field, and high-risk groups in the early stages of pregnancy will be taken proper disposal, the related complications will be reduced to ensure the safety of maternal.

Detailed Description
-----------------
This study focus on four hands: (1) to investigate different types of gestational sac implantation for pregnancy in caesarean women of childbearing age;(2) to explore the relationship between abnormal placenta planting disease in middle-late pregnancy and the different types of scar pregnancy (3) to explore the the value of ultrasound and serological markers for early diagnosis of placenta planting disease from scar pregnancy; (4) to compare the end and the influence of health economy of different termination method on scar pregnancy.

Official Title
-----------------
Abnormal Placenta Plant Disease Early Diagnosis and Individualized Treatment Research

Conditions
-----------------
Scarred Uterus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Single pregnancies with once cesarean section history see a doctor before gestational 8 weeks in our study center will continue to pregnancy, high patient compliance Exclusion Criteria: twins or multiple pregnancies hysteromyoma or adenomyoma stripping history history of intrauterine adhesions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Shanghai First Maternity and Infant Hospital<br> | |
| the Putuo District Maternity and Child Health Care Hospital<br> | |
| the Xinhua hospital affiliated to Shanghai jiaotong University<br> | |
| The Sixth people's hospital of Shanghai<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Placenta implanted |  | up to 37 gestational weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Placenta previa |  | up to 37 gestational weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Scar pregnancy, Placenta planting abnormal disease, Early diagnosis, Individualized treatment
Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.

Study Overview
=================
Brief Summary
-----------------
The main purpose of this study is to characterize the distribution, metabolism, and elimination (ADME) of Patupilone after a single intravenous administration in patients with advanced solid tumor malignancies

Official Title
-----------------
An Open-label Single Center Study to Characterize the Absorption, Distribution, Metabolism, and Elimination (ADME) of Patupilone (EPO906) After a Single Intravenous Administration of 10 mg/m2 [14C] Patupilone in Patients With Advanced Solid Tumor Malignancies.

Conditions
-----------------
Advanced Malignancies, Solid Tumors

Intervention / Treatment
-----------------
* Drug: Patupilone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years or older World Health Organization (WHO) Performance Status Score of: 0- you are fully active and more or less as you were before your illness, 1 - you cannot carry out heavy physical work, but can do anything else. Adequate hematological laboratory parameters No major impairment of renal or hepatic function Female patients must have a negative serum pregnancy test at screening. Exclusion Criteria: Severe and/or uncontrolled medical disease; Severe cardiac insufficiency with uncontrolled and/or unstable cardiac or coronary artery disease; Known diagnosis of human immunodeficiency virus (HIV) infection; Presence of any other active or suspected acute or chronic uncontrolled infection; Symptomatic brain metastases or leptomeningeal disease. Other protocol-defined inclusion/exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: EPO906<br> | Drug: Patupilone<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To characterize the pharmacokinetic profile of patupilone including any potential metabolite(s) in blood/plasma as well as the total radioactivity in blood and plasma. |  | one week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and tolerability will be assessed by AEs, SAEs and out of range lab values. |  | every 6 weeks | 
| Radiological scans will also be completed at approximately 6 weeks to asses anti-tumor activity. |  | every 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
EPO, Patupilone, Solid Tumors
Efficacy Evaluation of a Novel Diagnostic Assay Which is the Basis for Seaforia Diagnostic System

Study Overview
=================
Brief Summary
-----------------
Evaluation of specificity and sensitivity of Seaforia- an vitro diagnostic system for evaluating semen quality.

Detailed Description
-----------------
Quantities assessment of semen quality as defined by: Semen volume, semen pH, leukocytes concentration, sperm cells concentration, motile sperm cell concentration, total motile sperm cells threshold and sperm cells morphology

Official Title
-----------------
Efficacy Evaluation of a Novel Diagnostic Assay Which is the Basis for Seaforia Diagnostic System

Conditions
-----------------
Male Fertility

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Capable and willing to sign a consent form and participate in the study 20<Age<45 Male Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Semen Quality as determined by the following parameters: Semen volume |  | The same day as sevan evaluation according to the gold standard | 
| Semen pH |  | The same day as sevan evaluation according to the gold standard | 
| Leukocytes concentration |  | The same day as sevan evaluation according to the gold standard | 
| Sperm cells concentration |  | The same day as sevan evaluation according to the gold standard | 
| Motile sperm cell concentration |  | The same day as sevan evaluation according to the gold standard | 
| Total motile sperm cells threshold |  | The same day as sevan evaluation according to the gold standard | 
| Sperm cells morphology |  | The same day as sevan evaluation according to the gold standard |
Pandemia And Exercise in Turkey in University Students of Turkey

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine to what extent university students' physical activities are affected by staying at home during the pandemia.

Detailed Description
-----------------
The aim of our study is to determine to what extent university students' physical activities are affected by staying at home during the pandemia considering that they spend hours working by a computer. The state of physical inactivities will be questioned by an online survey for Inernational Physical Activity Questionnaire (short form). Then average energy expenditure following stepping and/or exercise will be asked from health application of mobile phones.

Official Title
-----------------
The Effect of Pandemia on Making Exercise In University Students of Turkey

Conditions
-----------------
Sedentary Behavior, Covid19

Intervention / Treatment
-----------------
* Other: survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Being a university student Having sufficient device infrastructure (cell phone or computer) to access the electronic survey Exclusion Criteria: Entering incorrect numbers for answers Those who have a disease / disability that prevents them from walking and exercising

Ages Eligible for Study
-----------------
Minimum Age: 17 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: survey|International Physical Activity Questionnaire (short form)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| International Physical Activity Score (short form) MEt-min/week | International Physical Activity Score (short form) during pandemia. Higher scores indicate better physical activity status. There is no strict range. | an average of 2 months, through study completion. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Energy expenditure while stepping | Energy expenditure while stepping during pandemia and before pandemia (Kcal) | an average of 2 months, through study completion. | 
| Energy expenditure while exercising | Energy expenditure while exercising during pandemia and before pandemia (Kcal) | an average of 2 months, through study completion. |
Evaluating AlloMax in Immediate Expander-Based Breast Reconstruction Study

Study Overview
=================
Brief Summary
-----------------
The study is a prospective multi-centered cohort study designed to determine the safety and efficacy of AlloMax in immediate expander-based breast reconstruction. Specifically, the study is designed to determine if sterility of human acellular dermal matrix results in a lower incidence of infection and seroma. The study will determine if gamma radiation, as a method of terminally sterilizing human acellular dermal matrix, has a negative impact on graft incorporation into the host tissue.

Official Title
-----------------
Evaluating Sterile Human Acellular Dermal Matrix in Immediate Expander-Based Breast Reconstruction: A Multi-centered Prospective Cohort Study

Conditions
-----------------
Malignant Neoplasm of the Breast, Acquired Absence of the Breast

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients having immediate breast reconstruction with tissue expanders Unilateral or bilateral reconstructions Ages 25 - 65 All breast cancer stages and types Exclusion Criteria: BMI > 35 Active smokers Diabetics History of radiation or planned radiation Immunocompromised patients

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Allomax<br>The cohort consists of immediate breast reconstruction patients who have AlloMax placed at the time of their tissue expander based immediate breast reconstruction. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Fluid Resuscitation With HES 200/0.5 10% in Severe Burn Injury

Study Overview
=================
Brief Summary
-----------------
HES 200/0.5 10% is equal to ringers lactat solution.

Detailed Description
-----------------
30 Patients were enrolled to the study, either to the hyperoncotic HES 200/0.5 (10%) group or to the crystalloids only group. After a treatment protocol of 72 hours we collected data about complications like pulmonary failure and abdominal compartment syndrome. Furthermore, we addressed the question of incidence of mortality and renal failure.

Official Title
-----------------
Fluid Resuscitation With HES 200/0.5 10% in Severe Burn Injury

Conditions
-----------------
Survival, Renal Failure

Intervention / Treatment
-----------------
* Drug: fluid resuscitation
* Drug: Fluid resuscitation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All burn victims with burned surface area bigger than 20% Exclusion Criteria: Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: HES<br>Fluid resuscitation with HES | Drug: fluid resuscitation<br>* fluid resuscitation with HES<br>|
| Placebo Comparator: ringers lactat<br>Standard treatment | Drug: Fluid resuscitation<br>* Fluid resuscitation in standardized fashion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intensive care unit mortality | 28 days | 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fluid amount during the first 72 hours | Fluid resuscitation after burn | 28 days |
Effect of a Real Time Radiation Monitoring Device on Radiation Exposure During Cardiac Catheterization

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine the impact of using a real time radiation exposure monitoring device on the patient and operator radiation exposure during cardiac catheterization. The hypothesis of the study is that use of a real time radiation exposure monitoring device during cardiac catheterization will decrease both patient and operator radiation exposure compared to no use of the monitoring device.

Official Title
-----------------
Effect of a Real Time Radiation Monitoring Device on Radiation Exposure During Cardiac Catheterization

Conditions
-----------------
Radiation Monitoring, Radiation Protection

Intervention / Treatment
-----------------
* Device: Radiation monitoring device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing clinically-indicated cardiac catheterization Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Use of a radiation monitoring device<br>Use of a radiation monitoring device that provides real-time auditory feedback on radiation exposure during cardiac catheterization | Device: Radiation monitoring device<br>* Radiation monitoring device (Bleeper Sv, Vertec Scientific Ltd, Berkshire, UK) that provides real-time auditory feedback on radiation exposure during cardiac catheterization<br>|
| No Intervention: No use of radiation monitoring device<br>No use of a radiation monitoring device that provides real-time auditory feedback on radiation exposure during cardiac catheterization | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Radiation exposure of the operator | Radiation exposure of the operator (measured in mrem by the real time monitoring device) | radiation exposure will be measured for the duration of the catheterization procedure, an expected average of one hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Radiation exposure of the patient | Radiation exposure of the patient, as measured by the X-ray machine using (a) air kerma dose, (b) dose area product, (c) fluoroscopy and cineangiography time | radiation exposure will be measured for the duration of the catheterization procedure, an expected average of one hour |
Genetics Study of In-stent Restenosis

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesized that genetic variants of G protein influence the development of restenosis and clinical outcome of patients receiving drug-eluting stents (DES).

Detailed Description
-----------------
Although drug-eluting stents (DES) have reduced restenosis rates compared with bare-metal stents, the restenosis rate is still high in the high-risk group. G protein plays important roles in the signal transduction leading to vascular smooth muscle proliferation. The initial and subsequent studies suggest that the T allele of C825T polymorphism is associated with enhanced transmembrane signaling via Gi proteins.

Official Title
-----------------
G Protein β3 Subunit (GNB3) Polymorphism and Restenosis of Coronary Drug-eluting Stents

Conditions
-----------------
Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who underwent follow-up angiography. All the patients must had been implanted with DES during the last two years. Exclusion Criteria: For the non-ISR group, the patients underwent follow-up angiography less than 6 months away from stent implanting.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| in-stent restenosis<br> | |
| non-in-stent restenosis<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In-stent restenosis |  | 6-24months after stent implanting | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| target lesion revascularization (TLR) |  | 6-24months after stent implanting | 
| re-myocardial infarction |  | 6-24months after stent implating | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
coronary stent implant, polymorphism, G protein, drug-eluting stent, restenosis
Impact of Mirabegron on Erectile Function in BPH Patients

Study Overview
=================
Brief Summary
-----------------
Evaluation of impact of Mirabegron on erectile function for patients treated for BPH

Detailed Description
-----------------
50 patients (Group A) will receive Mirabegron & alpha blocker 50 patients (Group B) will receive alpha blocker only Evaluation using IIEF 5 scoring system

Official Title
-----------------
Impact of Beta 3 Agonist Mirabegron on Erectile Function on Patients With Benign Prostate Hyperplasia

Conditions
-----------------
Males With Benign Prostatic Hyperplasia Symptoms

Intervention / Treatment
-----------------
* Drug: Mirabegron 50 MG
* Drug: Alpha Blockers


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All males above age 50 with LUTS due to BPH not candidate for prostatectomy Exclusion Criteria: males below age 50 neurologic abnormality Any indication for prostatectomy abnormal bladder contractility i.e diabetics

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group A Mirabegron<br>50 patients receiving Mirabegron 50 mg once daily & alpha blocker | Drug: Mirabegron 50 MG<br>* Mirabegron 50 mg daily dose and follow Up of erectile function using international index of erectile function 5 scoring system<br>|
| Group B alpha blocker only<br>50 patients receiving alpha blocker only | Drug: Alpha Blockers<br>* Alpha blocker daily and evaluation of erectile function using international index of erectile function 5 scoring system<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Impact of Mirabegron on erectile function | Using international index of erectile function 5 score system , least score 5 means severe erectile dysfunction and highest score 25 means no erectile dysfunction | 6 months |